leukotriene receptor antagonist provide further evidence of the role of leukotrienes Background -A study was undertaken to in the pathogenesis of exercise-induced determine whether montelukast, a new bronchoconstriction. potent cysteinyl leukotriene receptor (Thorax 1997;52:1030-1035 antagonist, attenuates exercise-induced bronchoconstriction. The relationship beKeywords: leukotriene receptor antagonist, exercisetween the urinary excretion of LTE 4 and induced bronchoconstriction, montelukast. exercise-induced bronchoconstriction was also investigated. Methods -Nineteen non-smoking asth-Cysteinyl leukotrienes, synthesised from matic patients with a forced expiratory arachidonic acid through the 5-lipoxygenase volume in one second (FEV 1 ) of [65% of pathway, have an important role in asthma. 1 the predicted value and a reproducible fall Leukotriene C 4 (LTC 4 ) is the dominant metain FEV 1 after exercise of at least 20% were bolite of arachidonic acid released in lung tissue enrolled. Subjects received placebo and but it is very unstable and quickly converted montelukast 100 mg once daily in the even-to leukotriene D 4 (LTD 4 ). In turn, LTD 4 is ing or 50 mg twice daily, each for two days, converted to a less potent metabolite, leukoin a three-period, randomised, double triene E 4 (LTE 4 ), which is excreted in the ilarly against exercise-induced broncho-available, selective, and potent cysteinyl leukoconstriction between plasma concentra-
conducted to determine whether montelukast and plasma concentrations of montelukast. The interval between treatment periods was at least attenuates exercise-induced bronchoconstriction and whether there is a relationship between four days. plasma concentration and effect by testing two dosage regimens producing different plasma concentrations. In addition, it was the aim of   For each subject exercise was performed on a this study to determine whether a sensitive assay could detect an increase in the urinary treadmill for six minutes. The gradient and speed of the treadmill was adjusted to achieve excretion of LTE 4 after exercise.
a work load of more than 80% of that subject's age-predicted maximum heart rate. Minor adjustments in work load were allowed in order to Methods  achieve the heart rate obtained in the prestudy visits. Pre-exercise spirometric values were Nineteen men aged 18-46 years with exerciseinduced bronchoconstriction were selected for measured in accordance with ATS guidelines 10 20 and five minutes before the challenge. The study. Each subject had at least a one year history of typical recurring symptoms of asthma best of three attempts at each time point were recorded and had to be at least 65% of the including dyspnoea, wheezing, and cough. Furthermore, during the prestudy evaluation each predicted value five minutes before exercise for the challenge to proceed. During the exercise subject had a forced expiratory volume in one second (FEV 1 ) of at least 65% of the predicted the subject wore a nose clip and breathed room air (constant ambient environment in air value for age, height, and sex. A 20% decrease in FEV 1 in response to standardised exercise conditioned laboratories). FEV 1 was measured immediately after exercise and at five, 10, 15, bronchoprovocation was required on two prestudy (qualifying) visits. All of the subjects were 30, 45, 60, 75 and 90 minutes. After exercise a agonist was administered to the patient if non-smokers for at least a year, with a smoking history of no more than one pack per day for the FEV 1 fell by ≤40% of the predicted value, if it was requested by the patient, or if the five years. Subjects were excluded if they had other illnesses based upon history, physical or investigator thought it was clinically indicated. laboratory examination, or had a respiratory infection within six weeks of the prestudy visit. Asthma medications were limited to rapidly    For the analysis of plasma drug concentration acting inhaled agonists and inhaled corticosteroids (maintained at a constant dose be-blood samples were collected from all subjects on the second prestudy visit and three minutes ginning four weeks before and throughout the study). All inhaled agonists were withheld before exercise on day 3 (study day) of each treatment period. The plasma specimens were for at least six hours and inhaled corticosteroids for at least one hour before the exercise chal-analysed for montelukast by high performance liquid chromatography (HPLC). The limit of lenges. None of the subjects were taking antihistamines or salmeterol prior to the study. detection was 30 ng/ml. The intraday precision values (percentage Relative Standard DeThe protocol was approved by the institutional review board and written informed consent was viation, %RSD) were in the range of 0-5.7% and the interday precision values (%RSD) at obtained from each subject.
concentrations of 51 and 2040 ng/ml were 10% and 3%, respectively.   The study was a double blind, randomised, three period, crossover trial. Treatments con-  4 
 
A separate objective of this study was to detersisted of either 100 mg of montelukast with the evening meal and placebo with breakfast, 50 mg mine whether exercise challenge in asthmatic patients with exercise-induced bronchoconof montelukast with the evening meal and breakfast, or placebo twice daily for two days striction is associated with increases in urinary concentrations of LTE 4 . Urine was collected (to achieve steady state plasma concentration). Thus, all subjects received a total of 100 mg/ one hour before and one and two hours after exercise. Urinary LTE 4 concentrations (pg/ml) day of montelukast or placebo in the 48 hour period prior to the test exercise challenge.
were expressed as the ratio of creatinine (mg/ ml) to correct for differences in urinary volume. All subjects returned to the pulmonary function laboratory on the third day between 15.00 Urinary LTE 4 was measured by a modified HPLC/radioimmunoassay originally described and 17.00 hours when the exercise challenge was performed 10-12 hours after the last dose by Tagari et al 11 and used clinically to demonstrate increases in urinary LTE 4 levels after of the twice daily regimen or 22-24 hours after the last dose of the once daily regimen. In antigen challenge in allergic asthmatic patients. 12 HPLC separation was carried out addition, routine physical examinations were performed, vital signs and electrocardiographic as described previously 13 and fractions were assayed in a competitive-binding radiochanges were measured, and blood and urine were collected for laboratory tests of safety and immunoassay using a commercially available peptidyl leukotriene antibody (Cascade Biomeasurement of montelukast plasma concentration and urine concentration of LTE 4 . chem Ltd, Berkshire, UK).
The between day precision of the radioAdherence was monitored by capsule counts, telephone contact by the study coordinator, immunoassay, expressed as coefficient of varigroup.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from ation (CV), was 6.0%, 8.5%, and 13.6% for 100 minutes minus the time required for the maximum decrease in FEV 1 from baseline to radioimmunoassay samples containing 104.2, 35.1, and 10.0 pg LTE 4 , respectively. Overall occur. recovery of 3 H-LTE 4 used as internal standard was 63%. Interday assay precision determined from analysis of pooled urine from healthy Area under the curve (AUC)
The area under the post-exercise FEV 1 persubjects was 13.3% and 11.4% for urine samples containing 54.5 and 20.2 pg LTE 4 /mg centage decrease through 60 minutes (AUC 0-60 ) was also determined. This parameter provides creatinine, respectively. The limit of reliable quantitation (LLRQ) was 5.24 pg LTE 4 /mg a single number that summarises the extent and duration of bronchoconstriction. The tracreatinine (based on a creatinine concentration of 142.5 mg/dl). LTE 4 values below this were pezoidal method was used to calculate the AUC 0-60 . Only areas below the pre-exercise reported as 2.5 pg LTE 4 /mg creatinine.
The urine creatinine assay is based on a baseline were included when computing the AUC 0-60 . modified Jaffe reaction as described by Chasson. 14 The between day precision at 150.1, 70.5, and 13.8 mg/dl were 5.6%, 3.4%, and 5.6%, respectively.
  4 The ability of exercise to increase urinary LTE 4 levels (pg/mg creatinine) was determined by analysing the change between the pre-exercise   baseline and the value two hours after exercise Exercise end points: general during the placebo period using the Wilcoxon The ability of montelukast to attenuate exsigned rank test. ercise-induced bronchoconstriction was determined by comparing three study end points among treatments: the maximum percentage   decrease in FEV 1 after exercise, the time re-
The analysis of variance (ANOVA) model for quired after maximal decrease for FEV 1 to a crossover study 15 was used to compare treatreturn to within 5% of the pre-exercise baseline ments for the three end points. The model value (recovery time), and the area above the included terms for subject, treatment, and post-exercise FEV 1 /time curve (AUC 0-60 min ).
period. Carryover effects were assessed by addThe mean of the 20 minute and five minute ing a carryover factor in the ANOVA model. pre-exercise measurements was used as the prePairwise comparisons of the treatment means exercise FEV 1 value. End points were calwere made using linear contrasts. 95% conculated for each individual and then averaged. fidence limits on differences or changes from If a patient required a bronchodilator during baseline were provided when appropriate with the post-exercise period or the FEV 1 value was p values of Ζ0.05 (with a two-tailed test) being not available, the last recorded FEV 1 was used considered significant. at all subsequent time points.
The study was designed to have 80% power (for 12 completing patients) to detect ( = 0.05, two-sided) a mean difference between Maximal decrease in FEV 1 treatment groups of 8.1 percentage points for The maximum percentage decrease in FEV 1 maximal percentage decrease in FEV 1 . after exercise was defined as:
pre-exercise FEV 1 -lowest FEV 1 (after exercise) pre-exercise FEV 1 ×100
Results

 
Nineteen subjects qualified and received alThe ability of the two montelukast dosage location numbers. Three subjects discontinued regimens to attenuate airway responsiveness before completing the three study periodsto exercise relative to placebo was defined as percentage protection from exercise-induced bronchoconstriction and calculated as follows: Additionally, if the post-exercise FEV 1 did not * Average of two pre-exercise challenges.
return to within 5% of baseline within 90 min- † Patient was using inhaled corticosteroids at a constant dose throughout the study.
utes the recovery time was assigned a value of (table 2) . The recovery one because of a urinary tract infection and time was significantly shorter with both active two because of asthma exacerbations unrelated treatments (p<0.001) than with placebo but to the exercise challenge (one each during did not differ between themselves. 50 mg twice daily and placebo periods). Of the The mean AUC 0-60 was 1166 (980)%, 368 16 subjects who completed the three study (218)%, and 387 (316)% (table 2) for the periods, data from two subjects were un-placebo, twice daily and once daily regimens, available for complete analysis. In one of these respectively. Both active treatments were sigpatients maximal exercise was not achieved due nificantly (p<0.001) smaller than placebo but to chest tightness (thought to be caused by did not differ between themselves. bronchoconstriction) in one period, and in the Beta agonist was administered to five patients second patient a technical problem with the while receiving placebo, three patients while spirometric measurement (moisture on the dia-receiving montelukast 100 mg once daily, but phragm of the pneumotachometer) prevented to no patients receiving montelukast 50 mg appropriate interpretation of the exercise chal-twice daily. lenge. The analysis was therefore based upon data from 14 subjects, only one of whom used concomitant inhaled corticosteroids (table 1) .
There were no important differences in air-   Plasma concentrations from 11 patients were way calibre before each exercise challenge for each treatment period with mean pre-exercise available for analysis. The pre-exercise mean (SD) plasma concentration of montelukast was baseline FEV 1 values ranging from 3.67 to 3.83 l. Additionally, there was no significant 1.27 (0.81) g/ml during the 50 mg twice daily regimen and 0.12 (0.09) g/ml for the 100 mg treatment or carryover effect. group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from choconstriction. This conclusion is based upon the observation that the concentration of LTE 4 increased after exercise challenge and montelukast, a potent and specific inhibitor of cysteinyl leukotrienes, attenuated the characteristic decrease in FEV 1 following exercise.
This study shows that urinary concentrations of LTE 4 increase after exercise in adults with mild asthma. Previous studies have shown an increase in urine concentrations of LTE 4 during severe episodes of worsening asthma and after bronchoprovocation with allergen or aspirin. 16 However, results from exercise studies have been conflicting. Previous adult studies were unable to detect increases in urinary levels of LTE 4 after exercise 17 while others detected increases after exercise in children with asthma but not in normal children. 18 A possible ex- 50 mg twice daily. On average, the plasma concentrations were almost 10 times higher at the trough of the twice daily regimen than at the If a agonist was administered after exercise the last value before its administration was used at all subsequent time points. This decision once daily dose. There was no correlation between the plasma concentration and the extent rule tends to underestimate the true end point values (maximal FEV 1 % fall, time to recovery, of protection from exercise-induced bronchoconstriction, as measured by either the and AUC). Because rescue occurs more frequently with placebo, the true difference be-AUC or the maximal percentage fall in FEV 1 .
tween active treatment and placebo will also be underestimated. Exercise challenges were generally re- 4   The urine concentration of LTE 4 increased producible -for example, between prestudy and placebo treatments -providing internal significantly (p<0.05) two hours after exercise challenge during placebo treatment from a validation to the conclusions of this study.
Using the parameters of the maximal fall mean (SD) of 34.3 (6.9) pg/mg creatinine to 73.7 (20.4) pg/mg creatinine (fig 2) . Neither in FEV 1 after exercise, previous studies have shown that 2 selective sympathomimetics may the pre-exercise LTE 4 nor the change in LTE 4 after exercise correlated with the maximal de-provide about 70% protection from exerciseinduced bronchospasm immediately after adcrease in FEV 1 after exercise. ministration which dissipates within six hours with short acting agents and within 12 hours with long acting agents. 20 Cromolyn provides   Clinical adverse events were infrequent and about 50% protection within the first two hours after administration. 21 In the present study there were no significant differences in frequencies between the three treatments (table montelukast produced about 50% protection 24 hours after dosing. The magnitude of in-3). There were no significant changes in laboratory measurements of blood haem-hibition is consistent with similar studies with cysteinyl leukotriene receptor antagonists 22 or atology and chemistry or urinalysis with montelukast treatments. a 5-lipoxygenase inhibitor. 23 Since leukotriene modifiers (5-lipoxygenase inhibitors or receptor antagonists) incompletely block the response to exercise, it is probable that other mediators Discussion The results of this study provide further evi-released in response to exercise are also involved in the pathogenesis of exercise-induced dence that cysteinyl leukotrienes are involved in the pathogenesis of exercise-induced bron-bronchospasm. 
